Innate Pharma S.A. (IPHA)

NASDAQ: IPHA · IEX Real-Time Price · USD
2.95
+0.14 (4.98%)
Mar 30, 2023, 12:29 PM EDT - Market open
4.98%
Market Cap 232.23M
Revenue (ttm) 61.36M
Net Income (ttm) -61.81M
Shares Out 83.56M
EPS (ttm) -0.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,367
Open 2.87
Previous Close 2.81
Day's Range 2.85 - 2.95
52-Week Range 1.90 - 3.97
Beta 0.33
Analysts Buy
Price Target 7.62 (+158.31%)
Earnings Date Mar 23, 2023

About IPHA

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumo... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 17, 2019
Employees 213
Stock Exchange NASDAQ
Ticker Symbol IPHA
Full Company Profile

Financial Performance

In 2022, Innate Pharma's revenue was 57.67 million, an increase of 133.47% compared to the previous year's 24.70 million. Losses were -58.10 million, 10.0% more than in 2021.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for IPHA stock is "Buy." The 12-month stock price forecast is $7.62, which is an increase of 158.31% from the latest price.

Price Target
$7.62
(158.31% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results1 for the year ending Dec...

1 week ago - Business Wire

Innate Pharma Announces Conference Call and Webcast for Full Year 2022 Financial Results

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday,...

2 weeks ago - Business Wire

Innate Pharma Provides Update on Silicon Valley Bank Exposure

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) has learned that Silicon Valley Bank has been closed by the California Department o...

2 weeks ago - Business Wire

Innate Pharma to Participate in Upcoming Investor Conferences

Innate Pharma to Participate in Upcoming Investor Conferences

1 month ago - Business Wire

Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today the expiration of the waiting period under the Hart-Scott-Rodino ...

2 months ago - Business Wire

Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today the publication in Nature Biotechnology of preclinical data showi...

2 months ago - Business Wire

Innate, Sanofi ink licensing deal for NK cells

Shares of Innate Pharma SA ADR [S: ipha] rallied 35.2% in premarket trading on Monday after the company said Sanofi SNY, -0.38% licensed its natural killer (NK) cell engager program as part of an alre...

Other symbols: SNY
3 months ago - Market Watch

Press Release: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology

Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology

Other symbols: SNY
3 months ago - GlobeNewsWire

Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:

Other symbols: SNY
3 months ago - Business Wire

Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:

4 months ago - Business Wire

Innate Pharma Reports Third Quarter Financial Results

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:

4 months ago - Business Wire

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for third quarter 2022 business update

5 months ago - Business Wire

Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the following presentations will be presented...

5 months ago - Business Wire

Innate Pharma 2023 Financial Calendar

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma 2023 financial calendar

5 months ago - Business Wire

Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that lacutamab, an anti-KIR3DL2 antibody, demonstr...

6 months ago - Business Wire

Innate Pharma Reports First Half 2022 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma reports first half 2022 financial results and business update

7 months ago - Business Wire

Innate Pharma Announces Conference Call and Webcast for First Half 2022 Business Update

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for first half 2022 business update

7 months ago - Business Wire

Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the following presentations will be presented...

7 months ago - Business Wire

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that a planned futility interim analysis of the I...

Other symbols: AZN
8 months ago - Business Wire

Innate Pharma to Participate in Upcoming Investor Conference

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are sch...

8 months ago - Business Wire

Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Sanofi has made the decision to progress IPH6...

9 months ago - Business Wire

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces IPH5201 Phase 2 study in lung cancer

Other symbols: AZN
10 months ago - Business Wire

Outcome of Innate Pharma's 2022 Annual General Meeting

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual Gen...

11 months ago - Business Wire

Innate Pharma Reports First Quarter 2022 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma reports first quarter 2022 financial results and business update

11 months ago - Business Wire